Moche M, Schneider G, Edwards P, Dehesh K, Lindqvist Y
Department of Medical Biochemistry and Biophysics, Doktorsringen 9A1, Karolinska Institutet, S-171 77 Stockholm, Sweden.
J Biol Chem. 1999 Mar 5;274(10):6031-4. doi: 10.1074/jbc.274.10.6031.
In the biosynthesis of fatty acids, the beta-ketoacyl-acyl carrier protein (ACP) synthases catalyze chain elongation by the addition of two-carbon units derived from malonyl-ACP to an acyl group bound to either ACP or CoA. The enzyme is a possible drug target for treatment of certain cancers and for tuberculosis. The crystal structure of the complex of the enzyme from Escherichia coli, and the fungal mycotoxin cerulenin reveals that the inhibitor is bound in a hydrophobic pocket formed at the dimer interface. Cerulenin is covalently attached to the active site cysteine through its C2 carbon atom. The fit of the inhibitor to the active site is not optimal, and there is thus room for improvement through structure based design.
在脂肪酸的生物合成过程中,β-酮酰基-酰基载体蛋白(ACP)合酶通过将源自丙二酸单酰-ACP的二碳单元添加到与ACP或辅酶A结合的酰基上,催化链的延长。该酶是治疗某些癌症和结核病的潜在药物靶点。来自大肠杆菌的该酶与真菌霉菌毒素浅蓝菌素复合物的晶体结构表明,抑制剂结合在二聚体界面形成的疏水口袋中。浅蓝菌素通过其C2碳原子与活性位点半胱氨酸共价连接。抑制剂与活性位点的契合并非最佳,因此通过基于结构的设计仍有改进空间。